Search hospitals > Michigan > Kalamazoo
Bronson Methodist Hospital
Claim this profileKalamazoo, Michigan 49007
Global Leader in Parotid Gland Cancer
Global Leader in Cancer
Conducts research for Breast Cancer
Conducts research for Adult T-Cell Leukemia/Lymphoma
Conducts research for Relapse
544 reported clinical trials
5 medical researchers
Summary
Bronson Methodist Hospital is a medical facility located in Kalamazoo, Michigan. This center is recognized for care of Parotid Gland Cancer, Cancer, Breast Cancer, Adult T-Cell Leukemia/Lymphoma, Relapse and other specialties. Bronson Methodist Hospital is involved with conducting 544 clinical trials across 679 conditions. There are 5 research doctors associated with this hospital, such as Kathleen J. Yost, Mark Goetting, MD, Gregory Wiggins, MD, and Chris Sloffer, MD.Area of expertise
1Parotid Gland Cancer
Global LeaderStage IV
Stage III
Stage I
2Cancer
Global LeaderStage IV
Stage I
Stage II
Top PIs
Kathleen J. YostBronson Methodist Hospital8 years of reported clinical research
Expert in Parotid Gland Cancer
Expert in Cancer
233 reported clinical trials
343 drugs studied
Mark Goetting, MDBronson Sleep Health3 years of reported clinical research
Studies Idiopathic Hypersomnia
Studies Excessive Daytime Sleepiness
3 reported clinical trials
4 drugs studied
Gregory Wiggins, MDBronson Methodist Hospital8 years of reported clinical research
Studies Middle Ear Disorders
Studies Degenerative Lumbosacral Spinal Conditions
1 reported clinical trial
2 drugs studied
Chris Sloffer, MDBronson Methodist Hospital8 years of reported clinical research
Studies Liver Disease
Studies Degenerative Lumbosacral Spinal Conditions
1 reported clinical trial
2 drugs studied
Clinical Trials running at Bronson Methodist Hospital
Breast Cancer
Lung Cancer
Cancer
Parotid Gland Cancer
Breast cancer
Non-Small Cell Lung Cancer
Ovarian Cancer
Multiple Myeloma
Bladder Cancer
Laryngeal Cancer
Low Dose Tamoxifen
for Breast Cancer
This phase III trial compares the effect of low dose tamoxifen to usual hormonal therapy, including aromatase inhibitors, in treating post-menopausal women with hormone positive, HER2 negative early stage breast cancer. Tamoxifen is in a class of medications known as antiestrogens. It blocks the activity of estrogen (a female hormone) in the breast. This may stop the growth of some breast tumors that need estrogen to grow. Aromatase inhibitors, such as anastrozole, letrozole, and exemestane, prevent the formation of estradiol, a female hormone, by interfering with an aromatase enzyme. Aromatase inhibitors are used as a type of hormone therapy to treat postmenopausal women with hormone-dependent breast cancer. Giving low dose tamoxifen may be more effective compared to usual hormone therapy in treating post-menopausal women with hormone-positive, HER2 negative early stage breast cancer.
Recruiting2 awards Phase 38 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Recruiting2 awards Phase 323 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Bronson Methodist Hospital?
Where is Bronson Methodist Hospital located?
Who should I call to ask about financial aid or insurance network?
What insurance does Bronson Methodist Hospital accept?
What awards or recognition has Bronson Methodist Hospital received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.